Dishman Pharmaceuticals and Chemicals (DPCL) on Tuesday said its Switzerland-based wholly owned subsidiary, Carbogen Amcis AG, has successfully completed USFDA Pre Approval Inspection (PAI) for a new high potency drug for a US multinational.
"Our Switzerland-based subsidiary Carbogen Amcis has successfully completed USFDA PAI for a new high potency drug for a US multinational," DPCL managing director J R Vyas said.
Post the approval, the company expects a business of around USD 10 million per annum from their existing customers, he added. Carbogen Amcis is a leading service provider, offering a portfolio of drug development and services to pharmaceutical and bio-pharmaceutical industry, at different stages of drug development.
DPCL, a contract research and manufacturing major (CRAM), earlier this year had announced to undertake an exercise to recast its Swiss subsidiary, after a lower than expected performance in the financial year 2011.
The sales of Carbogen Amcis AG in the quarter ending December last year stood at Rs 79.50 crore.
